ENANTONE LP 3.75 mg, powder and solvent for injectable suspension (s.c. or i.m.) with extended release bottle, 2 ml
Active ingredients: LEUPRORÉLINE
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended releasebottle, 2 mlintramusculaire;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ENANTONE LP 3,75 mg, poudre et solvant pour suspension injectable (S.C. ou I.M.) à libération prolongée
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire;sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 44,15 mg - 1 ampoule(s) en verre de 2 ml avec dispositif(s) d'administration avec seringue(s) avec aiguille(s) avec système de sécurité (safe system)
- Marketing authorisation holder
- TAKEDA FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Jun 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69230270CIP73757525CIP133400937575256Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LEUPRORÉLINEpoudre | 3,75 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.